0001567619-23-005257.txt : 20230317
0001567619-23-005257.hdr.sgml : 20230317
20230317161214
ACCESSION NUMBER: 0001567619-23-005257
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230315
FILED AS OF DATE: 20230317
DATE AS OF CHANGE: 20230317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McClure Matthew W.
CENTRAL INDEX KEY: 0001927121
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39617
FILM NUMBER: 23742689
MAIL ADDRESS:
STREET 1: C/O ALIGOS THERAPEUTICS, INC.
STREET 2: 1 CORPORATE DRIVE, 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aligos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001799448
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (800) 466-6059
MAIL ADDRESS:
STREET 1: ONE CORPORATE DR., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2023-03-15
0
0001799448
Aligos Therapeutics, Inc.
ALGS
0001927121
McClure Matthew W.
C/O ALIGOS THERAPEUTICS, INC.
1 CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
1.34
2023-03-15
4
A
0
75000
0
A
2033-03-15
Common Stock
75000
75000
D
1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
/s/ Lucinda Y. Quan, as attorney-in fact for Matthew W. McClure
2023-03-17